Evidence map›Paper›PMID 39849622›Full record

ArticleRadiation oncology (London, England)2025

The impact of radiation-related lymphocyte recovery on the prognosis of locally advanced esophageal squamous cell carcinoma patients: a retrospective analysis.

Hongshan Ji, Ping Zhang, Chanjun Zhen, Liyuan Fu, Dongjie Lv, Wenwen Bai, Rui Zhang, Jing Li, Hang Gao, Yajing Wang and 5 more

Abstract read
In one paragraph

Article in Radiation oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Hongshan JiDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Ping ZhangDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Chanjun ZhenDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Liyuan FuDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Dongjie LvDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Wenwen BaiDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Rui ZhangDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Jing LiDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Hang GaoDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Yajing WangDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Qiuying AnDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Yuhao SuDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Hanyu SiDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Xueying QiaoDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Zhiguo ZhouDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. 47700723@hebmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe impact of radiation-related lymphocyte recovery on prognosis in locally advanced esophageal squamous cell carcinoma (LA-ESCC) remains unclear.

methodsPatients with stage II-IVa ESCC who received definitive RT were screened. Collect absolute lymphocyte counts (ALCs) before, during, and after RT. The recovery status of lymphocytes was observed at one-month post-RT (P1) and three months post-RT (P3). Patients with relatively lower lymphocyte recovery levels at P1 were divided into Group a and those with higher levels were divided into Group b. Patients with relatively lower lymphocyte recovery levels at P3 were divided into Group A and those higher were divided into Group B. Kaplan-Merier's analysis and Cox analysis were conducted to compare survival outcomes. Binary logistic regression analyses was employed to ascertain factors associated with lymphocyte recovery.

results116 patients were enrolled. During RT, ALCs reached the bottom 5 weeks after RT started and 70.7% of patients experienced G3 lymphopenia. The median OS for Group a and Group b were 38.1 months and 14.4 months, p = 0.097. The median PFS for Group a and Group b were 14.2 months and 10.0 months, p = 0.037. Whereas, the median OS for Group A and Group B was 14.5 months and 22.2 months, p = 0.019. The median PFS for Group A and Group B were 8.4 months and 12.4 months, p = 0.021. Cox multivariable analysis revealed that higher lymphocyte recovery level at P3 was significantly associated with superior OS (p = 0.040, HR0.636) and PFS (p = 0.028, HR0.627). The logistic analysis identified a positive association between G4 lymphopenia during RT (p = 0.012, OR 7.742) and PTV dose < 60 Gy (p = 0.014, OR 2.655) with lymphocyte recovery.

conclusionsThe prognostic value of lymphocyte recovery status at P3 appears to be greater than that of lymphocyte recovery status at P1 for locally advanced ESCC patients. Radiation-related lymphocyte recovery might serve as a valuable prognostic factor in LA-ESCC.

Indexed as

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaLymphocytesAdultAgedAged, 80 and overFemaleHumansLymphocyte CountLymphopeniaMaleMiddle AgedPrognosisRetrospective StudiesSurvival RateEsophageal cancerLymphocyte recoveryPrognosisRadiotherapy

Identifiers

PMID39849622
PMCPMC11760108

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.